Canakinumab Subcutaneous and Novoeight recombinant
Determining the interaction of Canakinumab Subcutaneous and Novoeight recombinant and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: canakinumab
Brand name: Ilaris
Synonyms: Canakinumab
Generic Name: antihemophilic factor
Brand name: Advate, Adynovate, Afstyla, Eloctate with Fc Fusion Protein, Helixate FS, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil-M, Koate-DVI, Monoclate-P, Jivi, Obizur
Synonyms: Novoeight (recombinant)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Canakinumab Subcutaneous-Novolin 70/30
- Canakinumab Subcutaneous-Novolin 70/30 (Insulin NPH and Insulin Regular (InnoLets, Pens, and PenFills))
- Canakinumab Subcutaneous-Novolin 70/30 (Insulin NPH and Insulin Regular (Vials))
- Canakinumab Subcutaneous-Novolin N
- Canakinumab Subcutaneous-Novolin N (Insulin NPH (InnoLets, Pens, and PenFill Cartridges))
- Canakinumab Subcutaneous-Novolin N (Insulin NPH (Vials))
- Novoeight recombinant-Canasa
- Novoeight recombinant-Canasa Pac rectal
- Novoeight recombinant-Canasa rectal
- Novoeight recombinant-Cancidas
- Novoeight recombinant-Candesartan
- Novoeight recombinant-Candesartan and Hydrochlorothiazide